The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 27 March 2000.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 224K)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Ham, M.
Right arrow Articles by Neefjes, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Ham, M.
Right arrow Articles by Neefjes, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2000/4/1127/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 7, April 3, 2000 1127-1136


Original Article

Modulation of the Major Histocompatibility Complex Class II–associated Peptide Repertoire by Human Histocompatibility Leukocyte Antigen (HLA)-DO

Marieke van Hama, Marcel van Litha, Björn Lillemeierc, Esther Tjina, Ulrike Grüneberge, Dinah Rahmand, Liesbeth Pastoorsb, Krista van Meijgaardenf, Corinne Roucardg, John Trowsdalee, Tom Ottenhofff, Darryl Pappind, and Jacques Neefjesa
a Division of Tumor Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
b Division of Cellular Biochemistry, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
c Biochemical Regulatory Mechanisms Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, United Kingdom
d Protein Sequencing Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, United Kingdom
e Department of Pathology, University of Cambridge, Cambridge CB2 1QP, United Kingdom
f Department of Immunohaematology and Bloodbank, Leiden University Medical Center, 2333 2A Leiden, The Netherlands
g Groupe de Recherche sur les Lymphomes, Institut Albert Bonniot, 38706 La Tronche, France

Correspondence to: Marieke van Ham, Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel:31-20-512-2023 Fax:31-20-512-2029 E-mail:vanham{at}nki.nl.

Antigen presentation by major histocompatibility complex class II molecules is essential for antibody production and T cell activation. For most class II alleles, peptide binding depends on the catalytic action of human histocompatibility leukocyte antigens (HLA)-DM. HLA-DO is selectively expressed in B cells and impedes the activity of DM, yet its physiological role remains unclear. Cell surface iodination assays and mass spectrometry of major histocompatibility complex class II–eluted peptides show that DO affects the antigenic peptide repertoire of class II. DO generates both quantitative and qualitative differences, and inhibits presentation of large-sized peptides. DO function was investigated under various pH conditions in in vitro peptide exchange assays and in antigen presentation assays using DO- and DO+ transfectant cell lines as antigen-presenting cells, in which effective acidification of the endocytic pathway was prevented with bafilomycin A1, an inhibitor of vacuolar ATPases. DO effectively inhibits antigen presentation of peptides that are loaded onto class II in endosomal compartments that are not very acidic. Thus, DO appears to be a unique, cell type–specific modulator mastering the class II–mediated immune response induced by B cells. DO may serve to increase the threshold for nonspecific B cell activation, restricting class II–peptide binding to late endosomal compartments, thereby affecting the peptide repertoire.

Key Words: antigen presentation, immune response, selection, HLA-DM, autoimmunity


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS